Be the first to like this
Biopharmaceutical companies invest large amount of resources to develop and launch new products for metabolic therapeutic areas. However, the complexity of a new metabolic product launch is compounded by the many pitfalls that are part of the market-entry landscape.
®, LLC undertook this research to showcase current and future risk levels for various pitfalls across critical launch fronts that can derail a new metabolic product. Pharmaceutical launch executives can use this study to better understand the potential pitfalls and stumbling blocks that they'll have to navigate as part of a new metabolic product entering the market.
This study explores the executive insights, best practices and lessons learned to avoid common pitfalls while launching a new metabolic product into market.
About the Benchmark Class -
Forty four executives from 38 leading companies including Abbott, Amgen, Baxter, Bayer, Eisai, GlaxoSmithKline, Merck, Novartis, and Roche participated in this study. Majority of the respondents were at vice president or director level.
Section 1: Study Background --
Reviews the study background, the research approach, methodology, participant demographics, the benchmark class and key findings.
Section 2: Topical chapters --
Outlines valuable insights and findings from the study that includes pitfalls & stumbling blocks, lessons learned and best practices and future changes. Pitfalls chapter reviews current and future risk levels for these metabolic launch factors: product shaping, market shaping, physician, patient, payer, internal and regulatory.